HLTH 8052 Week 9 Antibiotic Stakeholder Analysis Example

Course	HLTH 8052 Advanced Issues in Global Public Health
Week	Week 9
Paper type	Stakeholder analysis
Length	About 880 words, 6 pages
Format	APA 7 student paper
School	Walden University
Program	PhD in Public Health
Updated	October 2026

Free sample paper for HLTH 8052 Week 9

Stakeholder Analysis: Who Gains, Who Pays and When if a Lower-Income Country Enforces Prescription-Only Sale of Antibiotics in Its Drug Shops

Student Name

Walden University

HLTH 8052: Advanced Issues in Global Public Health

Instructor Name

Month Day, Year

What this page is doingThe title adds timing to the usual gains-and-costs map, which is the feature that makes this stewardship problem hard.

Stakeholder Analysis: Who Gains, Who Pays and When if a Lower-Income Country Enforces Prescription-Only Sale of Antibiotics in Its Drug Shops

The Proposed Rule

The composite country in this analysis already classifies antibiotics as prescription-only medicines, as almost every country does on paper. In practice, licensed pharmacies and informal drug shops sell them on request. The proposed rule would enforce the prescription requirement through inspection and penalties. The problem is common: a systematic review of 38 studies from 24 countries estimated that 62% of requests or consultations for antibiotics in community pharmacies ended in supply without a prescription, rising to 78% when the patient asked for one by name (Auta et al., 2019). The analysis below asks who gains from enforcement, who pays, when each happens and what each party can do about it.

What this page is doingOpening with the gap between the law on paper and practice explains why enforcement, not a new law, is the policy at issue.

The Stakeholder Table

Table 1

Gains, Costs, Timing and Influence of Each Party

Party	What it gains	What it pays	When	Ability to shape the rule	Basis for the position \|
National medicines regulator	Credibility on stewardship; fewer resistant infections later	Inspection staff and budget; political pressure	Costs now, gains later	High: writes and enforces	Regulator's own mandate \|
Licensed pharmacists	Professional standing; fair competition with unlicensed sellers	Lost sales of antibiotics sold on request	Costs now	Moderate: professional council	Pharmacy council statements in comparable countries \|
Informal drug sellers	Little	Loss of a major product line; risk of closure	Costs now	Low formally, high in practice through evasion	Review evidence on non-prescription supply \|
Rural households	Lower risk of resistant infections over time	Longer trips to clinics; consultation costs; delayed treatment	Costs now, gains later and diffuse	Low	Access concern raised in global analysis \|
Public clinic prescribers	More patients; clearer role	Heavier workloads without added staff	Costs now	Moderate	Workforce constraints \|
Pharmaceutical distributor	Possible shift toward higher-value products	Lower antibiotic volumes	Costs now	Moderate: trade association	Commercial interest \|
Livestock producers	None directly	None directly unless the rule extends to veterinary sales	Later if extended	Moderate	Separate veterinary regulation \|
Future patients	Antibiotics that still work	Nothing	Gains later	None: not yet sick	Resistance evidence \|

Costs fall mostly now and on identifiable groups; gains arrive later and spread across people who cannot yet be named.

Reading the Time Column

The time column is what distinguishes this problem. Stewardship benefits accrue to people who are not yet sick, while the costs of enforcement fall on households who lose the nearest source of treatment today. A family two hours' walk from a clinic, with a child running a fever, experiences the rule as a barrier. The benefit, slower growth of resistance, will reach patients years from now, and no one in the family will see it. Laxminarayan and colleagues framed this tension in global terms: low- and lower-middle-income countries have gained life expectancy partly through better access to antimicrobials, and the challenge, which they describe as unique in global health, is to expand appropriate access while restricting inappropriate use (Laxminarayan et al., 2016). An analysis that treats stewardship as a benefit to the same people who bear its costs has misunderstood the problem.

The Payers the Rule Makes Visible

Three groups pay most. Rural households pay in travel, time and consultation fees, and some will go without treatment. Informal drug sellers pay through lost sales and, if enforcement is strict, closure; because they are often the only medicine outlet in a village, their closure also raises the household cost. Public clinic prescribers pay through added workload, since patients who once bought antibiotics at a shop now need a prescription. A rule that does not plan for these costs will be evaded: sellers will keep stock under the counter, and households will keep buying it.

Costs the Rule Could Offset

Some of these costs can be reduced without weakening the rule. The regulator could pair enforcement with a registration scheme that trains drug sellers to recognize danger signs and refer patients, turning the shops from the problem into part of the referral path. Public clinics in districts with the most drug shops could receive added prescribing staff, or nurses could be authorized to prescribe a short list of Access antibiotics. Transport vouchers for children with fever would address the household cost directly. Each offset has a price, and the stakeholder table shows who would be asked to pay it: mostly the ministry and its partners, the parties whose gains arrive later.

Where Influence Lies

The regulator has formal power, but informal sellers hold practical power through evasion, and enforcement in remote districts is thin. Licensed pharmacists may support the rule if it is enforced evenly against unlicensed competitors, which makes them potential allies. Future patients, the main beneficiaries, have no voice at all, and the regulator is the only party positioned to speak for them.

A Tiering Option

The regulator need not impose the rule uniformly. WHO's AWaRe classification groups antibiotics into Access, Watch and Reserve categories according to their importance and resistance risk (World Health Organization, 2023). A tiered rule could keep selected Access antibiotics available through trained and registered drug shops for common infections, while enforcing prescription for Watch antibiotics and banning Reserve antibiotics outside hospitals. That design moves some cost away from rural households while concentrating enforcement on the drugs where resistance matters most.

References

Auta, A., Hadi, M. A., Oga, E., Adewuyi, E. O., Abdu-Aguye, S. N., Adeloye, D., Strickland-Hodge, B., & Morgan, D. J. (2019). Global access to antibiotics without prescription in community pharmacies: A systematic review and meta-analysis. Journal of Infection, 78(1), 8-18. https://doi.org/10.1016/j.jinf.2018.07.001

Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016). Access to effective antimicrobials: A worldwide challenge. The Lancet, 387(10014), 168-175. https://doi.org/10.1016/S0140-6736(15)00474-2

World Health Organization. (2023). AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04

What the HLTH 8052 Week 9 instructions ask for

Week 9 calls for a stakeholder analysis of a proposed global health policy. The analysis should identify each party at a useful level of detail, describe what it gains and what it pays, and assess its ability to shape or block the policy. Faculty expect positions to be documented where possible rather than assumed. A table usually sits at the center, with the discussion spent on the rows that matter most. Attention to timing, who gains or pays now and who later, is especially valuable for problems like antimicrobial resistance. The paper should be about three to four pages plus the table, in APA format.

How this HLTH 8052 Week 9 example is built

The analysis opens by explaining that antibiotics are prescription-only on paper in most countries, citing Auta and colleagues' pooled estimates of 62% overall and 78% when patients ask by name. Table 1 lists eight parties with columns for gains, costs, timing, influence and the basis for each position, and a note summarizing the pattern. A section on the time column cites Laxminarayan and colleagues on the challenge of expanding appropriate access while restricting inappropriate use. The next section names the three groups who pay most: rural households, informal sellers and public prescribers. A new section proposes offsets, from seller training to added prescribing staff and transport vouchers. Influence is discussed separately, noting that future patients have no voice. The final section describes a tiered rule using the Access, Watch and Reserve categories.

Where the marks sit in the HLTH 8052 Week 9 rubric

Stakeholder analyses are graded on whether the parties who pay are visible. A table that carefully lists regulators and clinicians but leaves out the rural household whose access narrows has mapped the supporters and missed the costs. Timing is the second test, and an analysis that treats stewardship as benefiting the same people who bear its costs has misunderstood the problem. Cells should contain content a reader could check, such as lost revenue or a longer walk to a clinic, not one-word stances. Documented positions earn more than assumed ones. Discussion should focus on the rows that matter most. Proposals to offset costs or tier the policy show that the analysis can inform design. Table formatting and references in APA 7 finish the evaluation.

HLTH 8052 Week 9 help: mistakes that cost marks

Common mistakes in stakeholder papers include listing only organized groups with offices and spokespeople, giving each party a single word such as "supportive," and ignoring when costs and benefits arrive. Another is omitting the people the policy is meant to protect because they are not yet affected. To avoid these problems, include at least one household or patient group, one commercial interest and one party with no voice. For each, write what it gains and what it pays in concrete terms. Add a column for timing. Discuss the payers first. End with a design change that shifts some cost away from those least able to bear it. If you would like a stakeholder table built around your own policy question, one can be drafted for you as a reference.

Get a HLTH 8052 Week 9 example written to your instructions

Say which rule your section is analyzing, an antibiotic sales restriction or another stewardship measure, and send it with the Week 9 prompt and rubric. The table is filled from public sources and the analysis returns in 24-48h, free the first time. No regulator, pharmacy or employer's internal position is guessed at.

More HLTH 8052 papers and PhD in Public Health samples

HLTH 8052 Week 9 questions, answered

Does the analysis recommend restricting antibiotic sales?

It maps who gains and who pays under a restriction, and it names one design change that could reduce opposition. Whether to restrict is a position for your own paper. The sample describes documented effects and positions without endorsing a clinical practice or a regulatory choice on the site's behalf.

How many stakeholders belong in the table?

Seven to nine rows cover most versions, and your section's rubric decides the minimum. Composition is the real test: a regulator, a seller, a prescriber, a household, a commercial interest, and a party without a voice. Rows that duplicate each other's interests are merged rather than padded out.

Where can I find a free HLTH 8052 Week 9 sample paper?

The Week 9 stakeholder analysis for HLTH 8052 appears in full on this page, with an eight-row table of gains, costs, timing and influence for enforcing prescription-only antibiotic sales, and three references.

Why does the table list future patients as a stakeholder?

Because they are the main beneficiaries of slower resistance yet have no voice and bear no present cost, and leaving them out would make it impossible to explain why anyone should accept the costs that households and sellers face now.

How could the rule be tiered?

By using WHO's AWaRe grouping: selected Access antibiotics could remain available through trained, registered drug shops, while Watch antibiotics require a prescription and Reserve antibiotics stay in hospitals.